Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
Novo Nordisk's 'long game' on weight loss drugs sparks hope in science, but the Street is impatient
01:12am, Tuesday, 30'th Dec 2025
Novo Nordisk has had a difficult year as investors questioned the company's ability to translate its strides in pioneering GLP-1 drugs to financial gains. Scientists, however, say that Novo's medicine
Novo Nordisk Cuts Wegovy Prices in China Ahead of Patent Expiration
12:45pm, Monday, 29'th Dec 2025
Novo Nordisk A/S (NVO, Financials) cut the price of its top selling weight loss medicine Wegovy in China on Monday, expecting tougher competition from Chinese p
Novo Nordisk Halves Wegovy Prices In China Ahead Of Generic Threat
11:23am, Monday, 29'th Dec 2025
Novo Nordisk has lowered prices for its obesity drug Wegovy by 50% in China, ahead of generic competition.
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
10:00am, Monday, 29'th Dec 2025
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
The Obesity Pill Rush: Healthcare ETFs to Gain as FDA Nods to Novo Drug
09:50am, Monday, 29'th Dec 2025
FDA approval of NVO's oral Wegovy could reshape obesity care and lift healthcare ETFs, offering investors diversified exposure to the GLP-1 boom.
This Beaten-Down Stock Just Jumped By 8%. Time to Buy?
08:45am, Monday, 29'th Dec 2025
Pharmaceutical giant Novo Nordisk just earned approval for an oral version of Wegovy. This could help improve its position in the increasingly competitive weight loss market.
Novo cuts Wegovy prices in some Chinese provinces, local media reports
07:51am, Monday, 29'th Dec 2025
Danish drugmaker Novo Nordisk has nearly halved prices of its obesity drug Wegovy in some Chinese provinces, local media Yicai reported on Monday.
Novo Nordisk Cuts Wegovy Prices in China Ahead of Generic Threat
06:44am, Monday, 29'th Dec 2025
Novo Nordisk (NVO) has taken a more defensive pricing stance in China as competitive pressures around obesity treatments continue to build. Local media outlet Y
The Weight Loss Drug Competition Is Heating Up: These 2 Industry Leaders Just Filed Competing Drugs with the FDA.
04:23am, Monday, 29'th Dec 2025
Novo Nordisk's CagriSema could be a brand new growth driver for the company. Eli Lilly's orforglipron is breaking into a new, lucrative market.
Novo Nordisk: Oral Weight-Loss To The Rescue
10:00am, Sunday, 28'th Dec 2025
Novo Nordisk secured FDA approval for the first oral GLP-1 weight-loss drug, Wegovy, positioning it as a sector game changer. NVO's oral Wegovy pill demonstrated superior weight-loss efficacy versus E
Potentially 12%-15% Consistent Income: Monthly Options Series (January 2026)
08:00am, Sunday, 28'th Dec 2025
Selling options can generate 12-15% annual income but requires discipline, risk management, and due diligence. We explain why selling cash-covered puts and covered calls is a relatively safe choice fo
3 Drug Stocks to Buy at a Discount
04:28pm, Saturday, 27'th Dec 2025
Eli Lilly is currently leading the market for GLP-1 drugs, taking the pole position from Novo Nordisk. Novo Nordisk just got approval for a GLP-1 pill, which could again upend the dynamics for weight
Novo Nordisk A/S $NVO Stake Lessened by Carnegie Investment Counsel
05:14am, Saturday, 27'th Dec 2025
Carnegie Investment Counsel decreased its holdings in shares of Novo Nordisk A/S (NYSE: NVO) by 5.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exch
Oral Wegovy Approval Is The Critical 2026 Lifeline Novo Nordisk Needs
02:18pm, Friday, 26'th Dec 2025
Novo Nordisk A/S secured FDA approval for oral Wegovy, marking a pivotal expansion in the obesity treatment market. Oral GLP-1 therapies promise greater accessibility and a potentially larger addressa
Bear of the Day: Novo Nordisk (NVO)
01:46pm, Friday, 26'th Dec 2025
Novo Nordisk ( NVO ) is a global healthcare company and a prominent player in the diabetes market with a full portfolio of glucagon-like peptide 1 (GLP-1) receptor agonists, modern insulins and human
